Evidence map›Paper›PMID 34090218›Full record

ArticleCancer treatment and research communications2021

COVID-19 patients' sera induce epithelial mesenchymal transition in cancer cells.

Yasemin Saygideger, Aycan Sezan, Aslihan Candevir, Burcu Saygıdeğer Demir, Efraim Güzel, Oya Baydar, Ezgi Derinoz, Suheyla Komur, Ferit Kuscu, Ezgi Ozyılmaz and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancer treatment and research communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Cancer and COVID-19: Why are cancer patients more susceptible to COVID-19?Medical oncology (Northwood, London, England) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Yasemin SaygidegerDepartment of Pulmonary, Cukurova University School of Medicine, Adana 01330, Turkey; Department of Translational Medicine, Institute of Health Sciences, Cukurova University, Adana, Turkey; Department of Biotechnology, Institute of Natural and Applied Sciences, Cukurova University, Adana, Turkey. Electronic address: ysaygideger@cu.edu.tr.
Aycan SezanDepartment of Biotechnology, Institute of Natural and Applied Sciences, Cukurova University, Adana, Turkey.
Aslihan CandevirDepartment of Translational Medicine, Institute of Health Sciences, Cukurova University, Adana, Turkey; Department of Infectious Diseases, Cukurova University School of Medicine, Adana, Turkey.
Burcu Saygıdeğer DemirDepartment of Biotechnology, Institute of Natural and Applied Sciences, Cukurova University, Adana, Turkey.
Efraim GüzelDepartment of Pulmonary, Cukurova University School of Medicine, Adana 01330, Turkey.
Oya BaydarDepartment of Pulmonary, Cukurova University School of Medicine, Adana 01330, Turkey.
Ezgi DerinozDepartment of Biotechnology, Institute of Natural and Applied Sciences, Cukurova University, Adana, Turkey.
Suheyla KomurDepartment of Infectious Diseases, Cukurova University School of Medicine, Adana, Turkey.
Ferit KuscuDepartment of Infectious Diseases, Cukurova University School of Medicine, Adana, Turkey.
Ezgi OzyılmazDepartment of Pulmonary, Cukurova University School of Medicine, Adana 01330, Turkey.
Sedat KuleciDepartment of Pulmonary, Cukurova University School of Medicine, Adana 01330, Turkey.
Ismail HantaDepartment of Pulmonary, Cukurova University School of Medicine, Adana 01330, Turkey.
Hikmet AkkızDepartment of Gastroenterology, Cukurova University School of Medicine, Adana, Turkey.
Yesim TasovaDepartment of Infectious Diseases, Cukurova University School of Medicine, Adana, Turkey.
Cukurova University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Covid-19 Pneumonia of SARS-CoV-2 pandemic infection, persists to have high disease burden especially in cancer patients. Increased inflammation and thromboembolic processes are blamed to influence cancer patients more than the others but due to lack of knowledge regarding the pathophysiology of the both the virus itself and the response of the host, more basic and translational disease modeling research is needed to understand Cancer-Covid-19 interaction. In this study, serum samples from the patients, who were hospitalized due to Covid-19 pneumonia, applied to different cancer cells and cytotoxicity, motility, proliferation and gene expression analysis were performed. Serum samples derived from healthy volunteers and the fetal bovine serum that is used regularly in cell culture experiments used as controls. Hospitalized Covid-19 patients who had also cancer, were retrospectively screened, and their clinical course were recorded. Overall 12 Patient (PS) and 4 healthy serums (CS) were included in the experiments. PS applied cells showed increased motility in A549 cells as well as lost cell to cell connection in MCF7 and HCT116 cells, and induced expression of VIM, ZEB1 and SNAIL2 mRNA levels. Eight cancer diagnosed patients who were hospitalized due to Covid-19 between April and September 2020 were also reviewed retrospectively, which 5 of them were dead during SARS-CoV-2 infection. Thorax CT images of the 2 patients showed increased metastatic nodules in the lungs as of January 2021. The results of the study indicate that metastasis may be one of the prolonged consequences of COVID-19 pandemic in cancer sufferers.

Indexed as

Immune SeraAdultAgedCell Line, TumorCell MovementCell ProliferationCOVID-19Cytotoxicity, ImmunologicEpithelial-Mesenchymal TransitionFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasmsImmune SeraCancerCovid-19EMTInflammationSARS-CoV-2ZEB1, SNAIL2

Identifiers

PMID34090218
PMCPMC8146274
OpenAlexW3165402647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.